A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

被引：0
|
作者：
Nikol Snoeren
Emile E Voest
Andre M Bergman
Otilia Dalesio
Henk M Verheul
Rob AEM Tollenaar
Joost RM van der Sijp
Sander B Schouten
Inne HM Borel Rinkes
R van Hillegersberg
机构：
[1] University Medical Center Utrecht,Department of Surgical Oncology
[2] University Medical Center Utrecht,Department of Medical Oncology
[3] Antonie van Leeuwenhoek Hospital,Department of Medical Oncology
[4] Antonie van Leeuwenhoek Hospital,Department of Biometrics
[5] VU Medical Center De Boelelaan 1117,Department of Medical Oncology
[6] Department of Surgery,undefined
[7] Leiden,undefined
[8] Department of Surgery,undefined
来源：
BMC Cancer | / 10卷
关键词：
Vascular Endothelial Growth Factor; Bevacizumab; Liver Metastasis; Disease Free Survival; Oxaliplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
    Snoeren, Nikol
    Voest, Emile E.
    Bergman, Andre M.
    Dalesio, Otilia
    Verheul, Henk M.
    Tollenaar, Rob A. E. M.
    van der Sijp, Joost R. M.
    Schouten, Sander B.
    Rinkes, Inne H. M. Borel
    van Hillegersberg, R.
    BMC CANCER, 2010, 10
  • [2] A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer
    Voest, E. E.
    Snoeren, N.
    Schouten, S. B.
    Bergman, A. M.
    van Werkhoven, E.
    Loosveld, O. J. L.
    van Gulik, T. M.
    Smit, J. M.
    Cats, A.
    Boven, E.
    Hesselink, E.
    Rijken, A.
    Tol, M.
    Dalesio, O.
    Verheul, H. M.
    Tollenaar, R. A.
    van der Sijp, J.
    Rinkes, I. Borel
    van Hillegersberg, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study
    Snoeren, Nikol
    van Hillegersberg, Richard
    Schouten, Sander B.
    Bergman, Andre M.
    van Werkhoven, Erikv
    Dalesio, Otilia
    Tollenaar, Rob A. E. M.
    Verheul, Henk M.
    van der Sijp, Joost
    Rinkes, Inne H. M. Borel
    Voest, E. E.
    NEOPLASIA, 2017, 19 (02): : 93 - 99
  • [4] Pre- versus postoperative CAPOX plus bevacizumab (CAPOX-Bev) for resectable liver metastases from colorectal cancer (CLM): A randomized phase II/III trial (HiSCO-01).
    Takakura, Yuji
    Shinozaki, Katsunori
    Ikeda, Satoshi
    Egi, Hiroyuki
    Hirata, Yuzo
    Shimomura, Manabu
    Oshiro, Takafumi
    Hinoi, Takao
    Sumitani, Daisuke
    Nakahara, Masahiro
    Yoshimitsu, Masanori
    Honmyo, Naruhiko
    Kobayashi, Tsuyoshi
    Ohdan, Hideki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection
    Dewdney, A.
    Cunningham, D.
    Barbachano, Y.
    Chau, I.
    BRITISH JOURNAL OF CANCER, 2012, 106 (11) : 1718 - 1721
  • [6] Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection
    A Dewdney
    D Cunningham
    Y Barbachano
    I Chau
    British Journal of Cancer, 2012, 106 : 1718 - 1721
  • [7] Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604)
    Reinacher-Schick, A. C.
    Kubicka, S.
    Freier, W.
    Arnold, D.
    Dietrich, G.
    Geissler, M.
    Hegewisch-Becker, S.
    Graeven, U.
    Schmoll, H.
    Schmiegel, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] A Swiss multicentre phase II study of capecitabine plus oxaliplatin (CAPOX) in combination with preoperative pelvic radiotherapy in patients (pts) with locally advanced rectal cancer
    Koeberle, D.
    Burkhard, R.
    Von Moos, R.
    Winterhalder, R.
    Hess, V.
    Heitzmann, F.
    Ruhstaller, T.
    Terraciano, L.
    Bieri, G.
    Toepfer, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 244 - 244
  • [9] Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)
    Nakayama, Goro
    Mitsuma, Ayako
    Sunagawa, Yuki
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Matsui, Takanori
    Nakayama, Hiroshi
    Nakata, Kazuhiko
    Ishiyama, Akiharu
    Asada, Takahiro
    Umeda, Shinichi
    Ezaka, Kazuhiro
    Hattori, Norifumi
    Takami, Hideki
    Kobayashi, Daisuke
    Tanaka, Chie
    Kanda, Mitsuro
    Yamada, Suguru
    Koike, Masahiko
    Fujiwara, Michitaka
    Fujii, Tsutomu
    Murotani, Kenta
    Ando, Yuichi
    Kodera, Yasuhiro
    ONCOLOGIST, 2018, 23 (08): : 919 - 927
  • [10] Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
    Hoff, Paulo M.
    Hochhaus, Andreas
    Pestalozzi, Bernhard C.
    Tebbutt, Niall C.
    Li, Jin
    Kim, Tae Won
    Koynov, Krassimir D.
    Kurteva, Galina
    Pinter, Tamas
    Cheng, Ying
    van Eyll, Brigitte
    Pike, Laura
    Fielding, Anitra
    Robertson, Jane D.
    Saunders, Mark P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3596 - 3603
12345